LRMR Larimar Therapeutics, Inc. Stock Quote

LRMR [NASD]

Index	-	P/E	-	EPS (ttm)	-2.38	Insider Own	8.50%	Shs Outstand	39.94M	Perf Week	-2.32%
Market Cap	126.81M	Forward P/E	-	EPS next Y	-1.10	Insider Trans	359.29%	Shs Float	39.23M	Perf Month	17.83%
Income	-43.50M	PEG	-	EPS next Q	-0.40	Inst Own	37.80%	Short Float	0.71%	Perf Quarter	70.20%
Sales	-	P/S	-	EPS this Y	17.50%	Inst Trans	-5.54%	Short Ratio	0.88	Perf Half Y	-16.58%
Book/sh	2.73	P/B	1.23	EPS next Y	36.00%	ROA	-57.90%	Target Price	13.00	Perf Year	-72.49%
Cash/sh	1.46	P/C	2.31	EPS next 5Y	-	ROE	-71.50%	52W Range	1.53 - 13.69	Perf YTD	-68.77%
Dividend	-	P/FCF	-	EPS past 5Y	35.00%	ROI	-	52W High	-75.37%	Beta	0.85
Dividend %	-	Quick Ratio	7.40	Sales past 5Y	-	Gross Margin	-	52W Low	120.26%	ATR	0.33
Employees	31	Current Ratio	7.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	57.89	Volatility	10.09% 10.95%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	40.00%	Profit Margin	-	Rel Volume	0.27	Prev Close	3.33
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 11 AMC	Payout	-	Avg Volume	315.49K	Price	3.37
Recom	1.70	SMA20	7.70%	SMA50	31.13%	SMA200	-24.53%	Volume	84,698	Change	1.20%

Feb-15-22

Downgrade

William Blair

Outperform → Mkt Perform

Feb-10-21

Initiated

JMP Securities

Mkt Outperform

Feb-01-21

Initiated

William Blair

Outperform

$29

Sep-16-22 01:00PM	Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares GlobeNewswire -5.04%
Sep-14-22 07:04AM	Larimar Therapeutics Announces $70 Million Underwritten Offering GlobeNewswire +15.56%
07:01AM	Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreichs Ataxia Patients GlobeNewswire
Aug-11-22 04:05PM	Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results GlobeNewswire
Jul-28-22 04:05PM	Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders GlobeNewswire
08:00AM	Loading…
Jun-28-22 08:00AM	Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts GlobeNewswire
06:05AM	We're Keeping An Eye On Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Rate Simply Wall St.
Jun-02-22 08:00AM	Larimar Therapeutics Announces Upcoming Scientific Conference Presentations GlobeNewswire
May-19-22 08:00AM	Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinsons Disease and Movement Disorders Congress GlobeNewswire
May-12-22 07:00AM	Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results GlobeNewswire -7.91%
Apr-29-22 06:27AM	Despite recent gains, Larimar Therapeutics, Inc. (NASDAQ:LRMR) insiders are still down US$273k after purchasing last year Simply Wall St. -5.84%
Apr-13-22 10:40AM	Down 21.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR) Zacks
Mar-25-22 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results GlobeNewswire
Feb-16-22 11:57AM	Larimar Therapeutics' stock plunges on FDA decision; could implement cost-cutting measures American City Business Journals
Feb-14-22 04:01PM	Larimar Therapeutics Provides Update on CTI-1601 Clinical Program GlobeNewswire
06:53AM	Loading…
Jan-19-22 06:53AM	Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans? Simply Wall St.
Nov-22-21 07:00AM	Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference GlobeNewswire
Nov-20-21 08:40AM	In spite of Larimar Therapeutics, Inc.'s recent pullback, insiders still gained about US$85k after buying earlier this year. Simply Wall St.
Nov-15-21 07:00AM	Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference GlobeNewswire
Nov-12-21 07:00AM	Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results GlobeNewswire -8.72%
Sep-16-21 08:00AM	Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event GlobeNewswire -7.48%
Sep-02-21 04:01PM	Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference GlobeNewswire +5.81%
Aug-22-21 10:12AM	What You Need To Know About Larimar Therapeutics, Inc.'s (NASDAQ:LRMR) Investor Composition Simply Wall St.
Aug-19-21 07:00AM	Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress GlobeNewswire
Aug-12-21 07:00AM	Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results GlobeNewswire +17.79%
Aug-09-21 08:48AM	Why Larimar (LRMR) Might Surprise This Earnings Season Zacks
Jul-23-21 12:00PM	Larimar (LRMR) Upgraded to Buy: Here's Why Zacks
Jul-08-21 04:01PM	Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021 GlobeNewswire
Jun-11-21 07:00AM	Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-05-21 07:55PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR Newsfile
10:56PM	Loading…
Jun-02-21 10:56PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR GlobeNewswire
Jun-01-21 04:55AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR PR Newswire
May-29-21 10:59PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR Newsfile
May-25-21 05:41PM	Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing GlobeNewswire -10.59%
May-21-21 09:18AM	Larimar Therapeutics Announces $95 Million Private Placement Financing GlobeNewswire +11.17%
May-20-21 04:31PM	Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreichs Ataxia GlobeNewswire +10.17%
May-11-21 07:00AM	Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreichs Ataxia GlobeNewswire -36.28%
May-10-21 04:05PM	Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results GlobeNewswire -5.34%
Mar-04-21 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results GlobeNewswire
Mar-01-21 03:54AM	Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation Simply Wall St.
Feb-18-21 04:01PM	Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference GlobeNewswire
Dec-16-20 07:23PM	Is LRMR A Good Stock To Buy Now? Insider Monkey
Dec-15-20 08:00AM	Larimar Therapeutics Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-08-20 07:30AM	Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreichs Ataxia Patients and Provides Program Update GlobeNewswire
Nov-13-20 08:00AM	Larimar Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire +16.58%
Nov-10-20 08:00AM	Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results GlobeNewswire -6.12%
Oct-14-20 10:18PM	Hedge Funds Are Betting On Larimar Therapeutics, Inc. (LRMR) Insider Monkey
Oct-13-20 08:00AM	Larimar Therapeutics Announces Formation of Scientific Advisory Board GlobeNewswire +22.55%
Sep-21-20 09:58AM	Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit GlobeNewswire -6.19%
Sep-10-20 08:00AM	Larimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference GlobeNewswire +7.50%
Sep-01-20 12:47PM	What Is The Ownership Structure Like For Larimar Therapeutics, Inc. (NASDAQ:LRMR)? Simply Wall St.
Aug-11-20 07:00AM	Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results GlobeNewswire +9.43%
Aug-04-20 08:00AM	Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-28-20 08:00AM	Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreichs Ataxia GlobeNewswire
Jul-20-20 04:15PM	Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreichs Ataxia GlobeNewswire
May-29-20 04:05PM	Larimar Therapeutics to Present at Jefferies Virtual Healthcare Conference GlobeNewswire

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BEN-MAIMON CAROLE	President and CEO	Sep 16	Buy	3.15	31,746	100,000	56,829	Sep 19 07:00 AM
Celano Michael	Chief Financial Officer	Sep 16	Buy	3.15	31,746	100,000	31,746	Sep 19 07:00 AM
Flynn James E	Director	Sep 16	Buy	3.15	11,111,108	34,999,990	4,721,200	Sep 20 08:31 PM
Hamilton Thomas Edward	Director	Sep 16	Buy	3.15	317,460	999,999	507,590	Sep 20 06:54 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience